The Comptroller General's Office clarifies that the date for implementing the new criteria for "reimbursement of medication costs for government officials" has not yet been determined.

The Comptroller General's Department clarified news regarding the revised guidelines for reimbursement of medication costs for civil servants, emphasizing that the process is still in the public consultation phase and no definite implementation date has been set. They assured eligible individuals that their medical treatment will not be affected.
September 15, 2026 – Ms. Patricia Mongkolvanich, Director-General of the Comptroller General's Department, revealed that regarding information circulating on social media about revisions to the drug reimbursement guidelines in the civil servant healthcare welfare system, with a scheduled effective date of January 1, 2027, concerning three issues: co-payment for original drugs, the determination of drug dispensing periods, and the use of supporting documents in cases of lost drugs, along with a specified effective date, the Comptroller General's Department would like to clarify the facts as follows:
1. The revision of these guidelines is in line with the government's policy on increasing the efficiency of budget spending. These guidelines are still in the drafting and consultation phase with healthcare facilities and stakeholders. No official effective date has been set; therefore, the date reported in the news is not yet final. Once finalized, the Comptroller General's Department will officially notify healthcare facilities so they can implement them without disrupting services.
2. The claim that co-payments are required for “all” original-brand drugs is incorrect. Patients may only contribute if the drug is a generic or biosimilar registered with the Food and Drug Administration (FDA), has passed quality and manufacturing standards testing, and has been bioequivalence studied to provide equivalent therapeutic effects to the original drug, and the price charged by the healthcare facility is higher than the reimbursement rate set by the Department of Treasury.
3. The determination of medication dispensing duration is primarily intended for cases of initiating new medications, to allow for monitoring of symptoms and side effects before continuing medication, which is a principle of drug safety. For patients with chronic diseases whose symptoms are well controlled, the Comptroller General's Department will consider appropriate guidelines for continuous medication dispensing in collaboration with healthcare facilities and professional councils. The duration figures reported in the news are not final and are not intended to cause patients to make unnecessary hospital visits.
4. Regarding the issue of lost medication, discussions are still ongoing, and no conclusion has been reached or established as a guideline. The main focus of the discussion is on preventing duplicate medication reimbursement without justifiable reason. This will involve considering documentation formats that do not impose an undue burden on patients. The Comptroller General's Department is aware of the potential burden on the elderly and patients with chronic diseases and will not impose conditions that hinder access to essential medications.
"The Comptroller General's Department would like to emphasize that in future considerations of revising criteria, eligible individuals and their family members will continue to receive government medical welfare benefits and will still be entitled to reimbursement for medications not on the National Essential Drugs List when necessary and with medical justification. The attending physician will continue to prescribe medications based on indications and the patient's condition."































